Lefèvre-Groboillot David, Frapart Yves, Desbois Alain, Zimmermann Jean-Luc, Boucher Jean-Luc, Gorren Antonius C F, Mayer Bernd, Stuehr Dennis J, Mansuy Daniel
Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris 5, France.
Biochemistry. 2003 Apr 8;42(13):3858-67. doi: 10.1021/bi0272407.
The interaction of various N-alkyl- and N-aryl-N'-hydroxyguanidines with recombinant NOS containing or not containing tetrahydrobiopterin (BH(4)) was studied by visible, electronic paramagnetic resonance (EPR), and resonance Raman (RR) spectroscopy. N-Hydroxyguanidines interact with the oxygenase domain of BH(4)-free inducible NOS (BH(4)-free iNOS(oxy)), depending on the nature of their substituent, with formation of two types of complexes that are characterized by peaks around 395 (type I) and 438 nm (type II') during difference visible spectroscopy. The complex formed between BH(4)-free iNOS(oxy) and N-benzyl-N'-hydroxyguanidine 1 (type II') exhibited a Soret peak at 430 nm, EPR signals at g = 1.93, 2.24, and 2.38, and RR bands at 1374 and 1502 cm(-)(1) that are characteristic of a low-spin hexacoordinated Fe(III) complex. Analysis of its EPR spectrum according to Taylor's equations indicates that the cysteinate ligand of native BH(4)-free iNOS(oxy) is retained in that complex. Similar iron(III)-ligand complexes were formed upon reaction of 1 and several other N-hydroxyguanidines with BH(4)-free full-length iNOS and BH(4)-free nNOS(oxy). However, none of the tested N-hydroxyguanidines were able to form such iron(III)-ligand complexes with BH(4)-containing iNOS(oxy), indicating that a major factor involved in the mode of binding of N-hydroxyguanidines to NOS is the presence (or absence) of BH(4) in their active site. Another factor that plays a key role in the mode of binding of N-hydroxyguanidines to NOS is the nature of their substituent. The N-hydroxyguanidines bearing an N-alkyl substituent exclusively or mainly led to type II' iron-ligand complexes. Those bearing an N-aryl substituent mainly led to type II' complexes, even though some of them exclusively led to type I complexes. Interestingly, the K(s) values calculated for BH(4)-free iNOS(oxy)-N-hydroxyguanidine complexes were always lower when their substituents bore an aryl group (140-420 microM instead of 1000-3900 microM), suggesting the existence of pi-pi interactions between this group and an aromatic residue of the protein. Comparison of the spectral and physicochemical properties of the N-hydroxyguanidine complexes of BH(4)-free iNOS(oxy) (type II') with those of the previously described corresponding complexes of microperoxidase (MP-8) suggests that, in both cases, N-hydroxyguanidines bind to iron(III) via their oxygen atom after deprotonation or weakening of the O-H bond. The aforementioned results are discussed in relation with recent data about the transient formation of iron-product intermediates during the catalytic cycle of l-arginine oxidation by eNOS. They suggest that N-hydroxyguanidines could constitute a new class of good ligands of heme proteins.
通过可见光谱、电子顺磁共振(EPR)光谱和共振拉曼(RR)光谱研究了各种N-烷基和N-芳基-N'-羟基胍与含或不含四氢生物蝶呤(BH(4))的重组一氧化氮合酶(NOS)的相互作用。N-羟基胍与无BH(4)的诱导型NOS(无BH(4)的iNOS(oxy))的加氧酶结构域相互作用,这取决于其取代基的性质,在差示可见光谱期间形成两种类型的复合物,其特征在于在395(I型)和438 nm(II'型)附近有峰。无BH(4)的iNOS(oxy)与N-苄基-N'-羟基胍1(II'型)形成的复合物在430 nm处有一个Soret峰,在g = 1.93、2.24和2.38处有EPR信号,在1374和1502 cm(-)(1)处有RR带,这些是低自旋六配位Fe(III)复合物的特征。根据泰勒方程对其EPR光谱进行分析表明,天然无BH(4)的iNOS(oxy)的半胱氨酸配体保留在该复合物中。1与其他几种N-羟基胍与无BH(4)的全长iNOS和无BH(4)的nNOS(oxy)反应时形成了类似的铁(III)-配体复合物。然而,所测试的N-羟基胍均不能与含BH(4)的iNOS(oxy)形成这种铁(III)-配体复合物,这表明N-羟基胍与NOS结合模式中涉及的一个主要因素是其活性位点中BH(4)的存在(或不存在)。在N-羟基胍与NOS结合模式中起关键作用的另一个因素是其取代基的性质。仅带有或主要带有N-烷基取代基的N-羟基胍主要导致II'型铁-配体复合物。带有N-芳基取代基的那些主要导致II'型复合物,尽管其中一些仅导致I型复合物。有趣的是,当无BH(4)的iNOS(oxy)-N-羟基胍复合物的取代基带有芳基时,计算出的K(s)值总是较低(140 - 420 microM而不是1000 - 3900 microM),这表明该基团与蛋白质的芳香族残基之间存在π-π相互作用。将无BH(4)的iNOS(oxy)(II'型)的N-羟基胍复合物的光谱和物理化学性质与先前描述的微过氧化物酶(MP-8)的相应复合物的性质进行比较表明,在这两种情况下,N-羟基胍在去质子化或O-H键减弱后通过其氧原子与铁(III)结合。上述结果结合最近关于eNOS催化L-精氨酸氧化循环中铁-产物中间体瞬时形成的数据进行了讨论。它们表明N-羟基胍可能构成一类新的血红素蛋白良好配体。